101 results on '"Wilding, John P.H."'
Search Results
2. A systematic review of interventions to increase physical activity and reduce sedentary behaviour following bariatric surgery
3. Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus
4. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus
5. Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61.
6. Why I eat at night: A qualitative exploration of the development, maintenance and consequences of Night Eating Syndrome
7. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58
8. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial
9. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus
10. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
11. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction: Subanalysis From the DECLARE-TIMI 58 Trial
12. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
13. New insights into the treatment of obesity.
14. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus
15. Pathophysiology and aetiology of obesity
16. The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors
17. Correlations between night eating, sleep quality, and excessive daytime sleepiness in a severely obese UK population
18. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.
19. Pathophysiology and aetiology of obesity
20. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.
21. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program.
22. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
23. MRI thigh measurements predict whole‐body skeletal muscle mass in patients with type 2 diabetes: a comparison with DXA.
24. Effect of a Cooked Meat Meal on Serum Creatinine and Estimated Glomerular Filtration Rate in Diabetes-Related Kidney Disease
25. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
26. A Randomized, Placebo-Controlled Trial Assessing the Effects of Rosiglitazone on Echocardiographic Function and Cardiac Status in Type 2 Diabetic Patients With New York Heart Association Functional Class I or II Heart Failure
27. Screening for obstructive sleep apnoea in obesity and diabetes – potential for future approaches
28. Pathophysiology and aetiology of obesity
29. Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin: A Randomized Trial
30. Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
31. A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment
32. Regulation of the Fibrosis and Angiogenesis Promoter SPARC/Osteonectin in Human Adipose Tissue by Weight Change, Leptin, Insulin, and Glucose
33. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes.
34. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
35. Vitamin D receptor ligands attenuate the inflammatory profile of IL-1β-stimulated human white preadipocytes via modulating the NF-κB and unfolded protein response pathways
36. The influence of growth hormone replacement on heart rate variability in adults with growth hormone deficiency
37. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58.
38. The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial.
39. Cardiovascular outcome trials in obesity: A review.
40. Leptin and the control of obesity
41. Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats
42. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.
43. Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.
44. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials.
45. DAPAGLIFLOZIN AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND PRIOR MYOCARDIAL INFARCTION: A SUB-ANALYSIS FROM DECLARE TIMI-58 TRIAL
46. Liraglutide 3.0 mg in obese/overweight adults with or without prediabetes with baseline BMI
47. Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in individuals with prediabetes and obesity or overweight from the SCALE Obesity and prediabetes randomised, double-blind, placebo-controlled trial
48. Early weight loss responders to liraglutide 3.0 mg had greater weight loss, regression to normoglycaemia, and reduced T2D development at 3 years vs early non-responders: SCALE Obesity and Prediabetes
49. 127 - Hospitalization for Heart Failure and Death in New Users of SGLT-2 Inhibitors in Patients With and Without Cardiovascular Disease—CVD Real Study
50. Adipocytes in obesity: A perfect reservoir for SARS-CoV-2?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.